Cargando…
Synthesis of Novel, Dual-Targeting (68)Ga-NODAGA-LacN-E[c(RGDfK)](2) Glycopeptide as a PET Imaging Agent for Cancer Diagnosis
Radiolabeled peptides possessing an Arg-Gly-Asp (RGD) motif are widely used radiopharmaceuticals for PET imaging of tumor angiogenesis due to their high affinity and selectivity to α(v)β(3) integrin. This receptor is overexpressed in tumor and tumor endothelial cells in the case of numerous cancer c...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227980/ https://www.ncbi.nlm.nih.gov/pubmed/34073528 http://dx.doi.org/10.3390/pharmaceutics13060796 |
_version_ | 1783712635131265024 |
---|---|
author | Gyuricza, Barbara Szabó, Judit P. Arató, Viktória Szücs, Dániel Vágner, Adrienn Szikra, Dezső Fekete, Anikó |
author_facet | Gyuricza, Barbara Szabó, Judit P. Arató, Viktória Szücs, Dániel Vágner, Adrienn Szikra, Dezső Fekete, Anikó |
author_sort | Gyuricza, Barbara |
collection | PubMed |
description | Radiolabeled peptides possessing an Arg-Gly-Asp (RGD) motif are widely used radiopharmaceuticals for PET imaging of tumor angiogenesis due to their high affinity and selectivity to α(v)β(3) integrin. This receptor is overexpressed in tumor and tumor endothelial cells in the case of numerous cancer cell lines, therefore, it is an excellent biomarker for cancer diagnosis. The galectin-3 protein is also highly expressed in tumor cells and N-acetyllactosamine is a well-established ligand of this receptor. We have developed a synthetic method to prepare a lactosamine-containing radiotracer, namely (68)Ga-NODAGA-LacN-E[c(RGDfK)](2), for cancer diagnosis. First, a lactosamine derivative with azido-propyl aglycone was synthetized. Then, NODAGA-NHS was attached to the amino group of this lactosamine derivative. The obtained compound was conjugated to an E[c(RGDfK)](2) peptide with a strain-promoted click reaction. We have accomplished the radiolabeling of the synthetized NODAGA-LacN-E[c(RGDfK)](2) precursor with a positron-emitting (68)Ga isotope (radiochemical yield of >95%). The purification of the labeled compound with solid-phase extraction resulted in a radiochemical purity of >99%. Subsequently, the octanol–water partition coefficient (log P) of the labeled complex was determined to be −2.58. In addition, the in vitro stability of (68)Ga-NODAGA-LacN-E[c(RGDfK)](2) was investigated and it was found that it was stable under the examined conditions. |
format | Online Article Text |
id | pubmed-8227980 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82279802021-06-26 Synthesis of Novel, Dual-Targeting (68)Ga-NODAGA-LacN-E[c(RGDfK)](2) Glycopeptide as a PET Imaging Agent for Cancer Diagnosis Gyuricza, Barbara Szabó, Judit P. Arató, Viktória Szücs, Dániel Vágner, Adrienn Szikra, Dezső Fekete, Anikó Pharmaceutics Article Radiolabeled peptides possessing an Arg-Gly-Asp (RGD) motif are widely used radiopharmaceuticals for PET imaging of tumor angiogenesis due to their high affinity and selectivity to α(v)β(3) integrin. This receptor is overexpressed in tumor and tumor endothelial cells in the case of numerous cancer cell lines, therefore, it is an excellent biomarker for cancer diagnosis. The galectin-3 protein is also highly expressed in tumor cells and N-acetyllactosamine is a well-established ligand of this receptor. We have developed a synthetic method to prepare a lactosamine-containing radiotracer, namely (68)Ga-NODAGA-LacN-E[c(RGDfK)](2), for cancer diagnosis. First, a lactosamine derivative with azido-propyl aglycone was synthetized. Then, NODAGA-NHS was attached to the amino group of this lactosamine derivative. The obtained compound was conjugated to an E[c(RGDfK)](2) peptide with a strain-promoted click reaction. We have accomplished the radiolabeling of the synthetized NODAGA-LacN-E[c(RGDfK)](2) precursor with a positron-emitting (68)Ga isotope (radiochemical yield of >95%). The purification of the labeled compound with solid-phase extraction resulted in a radiochemical purity of >99%. Subsequently, the octanol–water partition coefficient (log P) of the labeled complex was determined to be −2.58. In addition, the in vitro stability of (68)Ga-NODAGA-LacN-E[c(RGDfK)](2) was investigated and it was found that it was stable under the examined conditions. MDPI 2021-05-26 /pmc/articles/PMC8227980/ /pubmed/34073528 http://dx.doi.org/10.3390/pharmaceutics13060796 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gyuricza, Barbara Szabó, Judit P. Arató, Viktória Szücs, Dániel Vágner, Adrienn Szikra, Dezső Fekete, Anikó Synthesis of Novel, Dual-Targeting (68)Ga-NODAGA-LacN-E[c(RGDfK)](2) Glycopeptide as a PET Imaging Agent for Cancer Diagnosis |
title | Synthesis of Novel, Dual-Targeting (68)Ga-NODAGA-LacN-E[c(RGDfK)](2) Glycopeptide as a PET Imaging Agent for Cancer Diagnosis |
title_full | Synthesis of Novel, Dual-Targeting (68)Ga-NODAGA-LacN-E[c(RGDfK)](2) Glycopeptide as a PET Imaging Agent for Cancer Diagnosis |
title_fullStr | Synthesis of Novel, Dual-Targeting (68)Ga-NODAGA-LacN-E[c(RGDfK)](2) Glycopeptide as a PET Imaging Agent for Cancer Diagnosis |
title_full_unstemmed | Synthesis of Novel, Dual-Targeting (68)Ga-NODAGA-LacN-E[c(RGDfK)](2) Glycopeptide as a PET Imaging Agent for Cancer Diagnosis |
title_short | Synthesis of Novel, Dual-Targeting (68)Ga-NODAGA-LacN-E[c(RGDfK)](2) Glycopeptide as a PET Imaging Agent for Cancer Diagnosis |
title_sort | synthesis of novel, dual-targeting (68)ga-nodaga-lacn-e[c(rgdfk)](2) glycopeptide as a pet imaging agent for cancer diagnosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227980/ https://www.ncbi.nlm.nih.gov/pubmed/34073528 http://dx.doi.org/10.3390/pharmaceutics13060796 |
work_keys_str_mv | AT gyuriczabarbara synthesisofnoveldualtargeting68ganodagalacnecrgdfk2glycopeptideasapetimagingagentforcancerdiagnosis AT szabojuditp synthesisofnoveldualtargeting68ganodagalacnecrgdfk2glycopeptideasapetimagingagentforcancerdiagnosis AT aratoviktoria synthesisofnoveldualtargeting68ganodagalacnecrgdfk2glycopeptideasapetimagingagentforcancerdiagnosis AT szucsdaniel synthesisofnoveldualtargeting68ganodagalacnecrgdfk2glycopeptideasapetimagingagentforcancerdiagnosis AT vagneradrienn synthesisofnoveldualtargeting68ganodagalacnecrgdfk2glycopeptideasapetimagingagentforcancerdiagnosis AT szikradezso synthesisofnoveldualtargeting68ganodagalacnecrgdfk2glycopeptideasapetimagingagentforcancerdiagnosis AT feketeaniko synthesisofnoveldualtargeting68ganodagalacnecrgdfk2glycopeptideasapetimagingagentforcancerdiagnosis |